Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Ho, Alan L ^a,b   Musi, Elgilda ^a   Ambrosini, Grazia ^a   Nair, Jayasree S ^a   Deraje Vasudeva, Shyamprasad ^a   de Stanchina, Elisa ^a   Schwartz, Gary K ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZD 8055; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN MCL 1; SELUMETINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAF GENE; CANCER GENETICS; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CELL MUTANT; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; GENE; GENE FUNCTION; GENOTYPE; GNAQ GENE; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PREDICTION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UVEA MELANOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENOTYPE; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; MORPHOLINES; MULTIPROTEIN COMPLEXES; MUTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, IGF TYPE 1; TOR SERINE-THREONINE KINASES; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863671580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040439     Document Type: Article

References (53)

1. Patel M, Smyth EC, Chapman PB, Wolchok JD, Schwartz GK, et al. (2011) Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma. Clin Cancer Res.
2. Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, et al. (2003) Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 83: 1771-1776.
3. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, et al. (2005) Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 92: 2032-2038.
4. Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, et al. (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88: 1403-1405.
5. Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, et al. (2006) Detection of BRAF gene mutation in primary choroidal melanoma tissue. Cancer Biol Ther 5: 225-227.
6. Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, et al. (2003) Lack of BRAF mutations in uveal melanoma. Cancer Res 63: 5712-5715.
7. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, et al. (2003) Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 278: 42409-42418.
8. Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, et al. (2006) Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. J Biol Chem 281: 9238-9250.
9. Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, et al. (2004) The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res 14: 203-205.
10. Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, et al. (2008) Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 49: 23-27.
11. Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, et al. (2008) The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer 99: 1673-1677.
12. van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, et al. (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457: 599-602.
13. van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, et al. (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363: 2191-2199.
14. Dummer R, Robser C, Chapman PB, Sosman JA, Middleton M, et al. (2008) AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J Clin Oncol 26: Suppl: abstract 9033.
15. Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, et al. (2006) High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 24: 288-295.
16. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
17. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70: 288-298.
18. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
19. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032.
20. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, et al. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13: 1576-1583.
21. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
22. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, et al. (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239.
23. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, et al. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51.
24. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, et al. (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13: 1422-1437.
25. Ruggero D, Sonenberg N, (2005) The Akt of translational control. Oncogene 24: 7426-7434.
26. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, et al. (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 105: 10853-10858.
27. Faber AC, Li D, Song Y, Liang MC, Yeap BY, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106: 19503-19508.
28. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, et al. (2010) Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5: e14124.
29. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, et al. (2010) Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 5: e13026.
30. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
31. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, et al. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70: 8736-8747.
32. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297.
33. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
34. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, et al. (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70: 6804-6814.
35. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71: 2750-2760.
36. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, et al. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293.
37. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31: 446-457.
38. Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A, (2008) Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 7: 307-315.
39. Atefi M, von Euw E, Attar N, Ng C, Chu C, et al. (2011) Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway. PLoS One 6: e28973.
40. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, et al. (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1: 248-259.
41. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
42. Naus NC, Zuidervaart W, Rayman N, Slater R, van Drunen E, et al. (2000) Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int J Cancer 87: 151-153.
43. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, et al. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752.
44. de Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, et al. (1995) Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 62: 155-161.
45. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, et al. (2004) Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 279: 31769-31779.
46. Luyten GP, Mooy CM, de Jong PT, Hoogeveen AT, Luider TM, (1993) A chicken embryo model to study the growth of human uveal melanoma. Biochem Biophys Res Commun 192: 22-29.
47. Ma D, Luyten GP, Luider TM, Niederkorn JY, (1995) Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci 36: 435-441.
48. Sun Y, Tran BN, Worley LA, Delston RB, Harbour JW, (2005) Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci 46: 1561-1564.
49. Braun RD, Abbas A, (2006) Orthotopic human choroidal melanoma xenografts in nude rats with aggressive and nonaggressive PAS staining patterns. Invest Ophthalmol Vis Sci 47: 7-16.
50. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
51. Motwani M, Delohery TM, Schwartz GK, (1999) Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5: 1876-1883.
52. Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, et al. (2008) Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 7: 890-896.
53. Nair JS, de Stanchina E, Schwartz GK, (2009) The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 15: 2022-2030.